13F Holdings
中文EN

BIO BIO-RAD LABORATORIES, INC.

Laboratory Analytical Instruments · NYSE · SEC CIK 12208 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.4%
TTM net income YoY251.3%
TTM EPS YoY254.8%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—

Margins

Gross margin51.3%
Operating margin-2.4%
Net margin39.5%
FCF margin12.7%
EBITDA margin—

Returns

ROE14.3%
ROA10.0%
ROIC (approx.)-0.6%
Asset turnover0.25x

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.11x
Current ratio3.18x
Interest coverage-1.27x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio5.4%
Payout ratio—
Capex / revenue5.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.58B$2.57B$2.67B$2.80B$2.92B
Cost of revenue$1.24B$1.19B$1.24B$1.23B$1.28B
Gross profit$1.34B$1.38B$1.43B$1.57B$1.64B
R&D expense$275.60M$295.90M$247.40M$256.90M$260.64M
SG&A expense$844.30M$814.00M$841.70M$827.80M$877.12M
Operating income$47.20M$269.00M$337.80M$482.60M$500.34M
Interest expense$49.00M$48.90M$49.40M$38.10M$1.55M
Pretax income$995.50M-$2.34B-$850.10M-$4.70B$5.45B
Income tax$235.60M-$498.30M-$212.80M-$1.08B$1.19B
Net income$759.90M-$1.84B-$637.30M-$3.63B$4.25B
EBITDA$212.60M$420.60M$483.70M$619.90M$637.94M
EPS (basic)27.87-65.36-21.82-121.79142.61
EPS (diluted)27.85-65.36-21.82-121.79140.83
Weighted avg. shares (diluted)27.28M28.21M29.21M29.79M30.21M
Banking
Provision for credit losses$1.40M$0$0$7.50M$0
Balance sheet
Cash & equivalents$529.80M$489.80M$403.80M$434.50M$471.10M
Short-term investments$1.01B$1.18B$1.20B$1.36B$399.13M
Receivables$460.60M$452.50M$489.00M$494.64M$423.54M
Inventory$740.70M$760.00M$780.50M$719.32M$572.24M
Current assets$2.91B$3.03B$3.05B$3.16B$1.99B
PP&E, net$539.90M$528.10M$529.00M$498.61M$511.64M
Goodwill$579.80M$410.50M$413.60M$406.50M$347.30M
Intangibles$174.30M$293.60M$320.50M$332.15M$253.94M
Total assets$10.58B$9.36B$12.30B$13.50B$17.80B
Current liabilities$517.00M$467.80M$522.80M$568.71M$680.94M
Long-term debt$1.20B$1.20B$1.20B$1.20B$10.51M
Total debt$1.20B$1.20B$1.20B$1.20B$10.51M
Total liabilities$3.12B$2.79B$3.56B$3.89B$4.11B
Shareholders' equity$7.45B$6.57B$8.74B$9.62B$13.69B
Net debt$671.90M$710.60M$795.30M$763.20M-$460.59M
Cash flow statement
Operating cash flow$532.20M$455.20M$374.90M$194.40M$669.46M
Capital expenditure$157.60M$165.60M$156.70M$112.80M$133.75M
Free cash flow$374.60M$289.60M$218.20M$81.60M$535.72M
Investing cash flow-$189.70M-$160.20M$20.20M-$1.21B-$797.38M
Financing cash flow-$283.20M-$218.80M-$425.60M$973.60M-$55.43M
Depreciation & amortization$165.40M$151.60M$145.90M$137.30M$137.60M
Stock-based compensation$58.00M$62.30M$61.30M$60.90M$51.20M
Share buybacks$295.50M$203.60M$428.70M$215.70M$50.00M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.